Osteoporosis is the progressive, systemic skeletal disease characterized by decreased bone mass and micro-architectural deterioration of bone tissue leading to bone fragility and increased susceptibility to fractures.
The more risk factors (eg history, of fracture, advanced age, comorbidities, impaired vision) that are present, the greater the risk of fracture.


Bone Mineral Density Measurements
  • Bone mineral density (BMD) measurements give an accurate reflection of bone mass & confirm diagnosis of osteoporosis
  • An excellent predictor of future fracture risk
Methods of Bone Mineral Density Measurement
  • Dual energy X-ray absorptiometry (DXA) of hip & spine
    • Gold standard
    • Diagnose osteoporosis based on bone mineral density (BMD) mesasurement of the hips (conventionally)
    • Monitor therapeutic response based on bone mineral density (BMD)

Bone Mineral Density T-score

WHO Recommended Values* for Diagnosis of Osteoporosis
Bone Mineral Density T-score (SD) Definition
T ≥ -1 Normal
T < -1 to < -2.5 Osteopenia (low bone mass)
T ≤ -2.5 Osteoporosis
T ≤ -2.5 + fracture Severe/established osteoporosis
*Values are based on dual energy X-ray absorptiometry (DXA)
T-score: A comparison with young normal adult mean of the same sex
  • Quantitative CT scan (QCT)
    • Used as an alternative technique when dual energy X-ray absorptiometry (DXA) is not available
    • Measures bone strength in the axial skeleton & volumetric bone density of the vertebra & hip
    • Has higher radiation dose compared to dual energy X-ray absorptiometry (DXA)
  • Trabecular Bone Score (TBS)
    • Evaluates microarchitectural texture of the bone
    • Highly sensitive in predicting fracture risk
Screening Methods (Not for Diagnosis or Monitoring)
  • Peripheral dual-energy X-ray absorptiometry (pDXA)
  • CT-based assessments: Peripheral QCT
  • Quantitative ultrasound densitometry (QUS) of heel, tibia, patella & other peripheral skeletal sites
If fracture is present: Physical exam, lab tests & radiologic tests should also be conducted to exclude underlying diseases that mimic, aggravate or cause osteoporosis eg secondary osteoporosis

Laboratory Tests

  • CBC, erythrocyte sedimentation rate (ESR)
  • Renal function tests
  • Electrolytes (eg ionized calcium [Ca], phosphate, magnesium [Mg])
  • Creatinine, albumin, aspartate aminotransferase (AST), alkaline phosphatase
  • Urinalysis
  • Bone turnover markers
    • Identifies patients at high risk for fractures
    • Used to evaluate efficacy & compliance to current treatment
    • Eg serum C-telopeptide (CTX), osteocalcin, N-terminal propeptide of type 1 procollage (P1NP), tissue transglutaminase antibodies (IgA & IgG), serum protein electrophoresis (SPEP)
  • Others (eg thyroid function as indicated, parathyroid hormone)


  • Scintigraphic bone studies, X-ray of lateral thoraco-lumbar spine or hip (as indicated)
Vertebral Imaging
  • Recommended for the following:
    • Women ≥70 year & men ≥80 year with bone mineral density (BMD) T-score ≤-1.0 at the spine, total hip, or femoral neck
    • Women 65-69 year & men 70-79 year with bone mineral density (BMD) T-score ≤-1.5 at the spine, total hip, or femoral neck
    • Postmenopausal women & men ≥50 year with low trauma fracture during adulthood, historical height loss (current height - peak height at 20 year) by >1.5 inches, prospective height loss (current height - recently documented height) by ≥0.8 inches, &/or currently or previously on long-term glucocorticoid treatment
    • Other bone mineral density (BMD) measurements are unavailable


Indications for Bone Mineral Density (BMD) Measurements
  • All women ≥65 year or women <65 year with ≥1 risk factor for fracture/osteoporosis [recommended by the U.S. National Osteoporosis Foundation (NOF)] or using Osteoporosis Self-Assessment Tool for Asians (OSTA) to assess risk & the need for bone mineral density (BMD) measurement
  • All men >70 year of age, men >50-69 year with risk factors, & men >50 year with history of fracture during adulthood
  • Corticosteroid therapy equivalent to ≥5 mg/day of prednisone for ≥3 month
  • Low body mass index (BMI) (<127 lb or BMI <20 kg/m2), loss of height, thoracic kyphosis
  • Presence of estrogen deficiency (eg prolonged secondary amenorrhea, hypogonadism, premature natural or surgical menopause <45 year, early menopause [<40 year old])
  • Presence of conditions related to osteoporosis (eg hyperparathyroidism, hyperthyroidism, anorexia nervosa, malabsorption, Cushing’s syndrome, prolonged immobilization, rheumatoid arthritis)
  • Radiological evidence of osteopenia or vertebral deformity
  • Women considering treatment for osteoporosis & if bone mineral density (BMD) measurement facilitates decision
  • Postmenopausal women who have had any type of fracture as an adult after age of 50 year
Some authorities recommend that patients >65 year with multiple risk factors or prevalent osteoporotic fracture be started on treatment for osteoporosis without bone mineral density (BMD) measurements

WHO Fracture Risk Assessment Model (FRAXTM)
  • Developed to calculate the 10-year risk of osteoporosis fracture, with or without BMD values, based on individual factors (eg sex, age, ethnicity, family history, previous fracture, glucocorticoid treatment, smoking status, alcohol consumption, rheumatoid arthritis, low BMI)
    • Level of fracture probability will vary between countries
    • Malaysia Osteoporosis Society recommends using the Singaporean prediction algorithm until more Malaysian data are available
  • Useful in identifying among the group of patients with osteopenia those at higher risk of fracture
  • Limitations of FRAXTM include lack of detail on some risk factors (eg smoking, prior fracture, effects of glucocorticoids), non-inclusion of other known risk factors (eg biochemical markers, falls)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Editor's Recommendations
Most Read Articles
01 Jan 2016
The thyroid gland was hypovascular, coarse,  hyperechoic, and had substantially decreased in mean total volume among Graves' hyperthyroidism patients following radioiodine therapy, based on a study
02 Jun 2017

Abnormal lung function and histological features have been found in diabetics, and there is enough evidence showing that the lungs are another target organ of diabetes, says a specialist at the 9th Diabetes Complications Conference and Grand Rounds organized by the National Diabetes Institute (NADI).

4 days ago
Global hypomethylation of Alu appears to increasingly influence distant metastatic differentiated thyroid cancer (DTC), poorly (P)DTC and anaplastic (A)TC, according to a recent study. This suggests that the epigenetic entity may be involved in thyroid cancer progression and dedifferentiation.
01 Nov 2015
Increased serum prolidase levels in Grave's disease patients without ophthalmopathy signs are positively associated with oxidative stress parameters as shown in a study.